Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as many months.

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...

Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects ...

Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...

FDA places Kezar's lupus trial on hold in wake of ... “Through our work in systemic lupus erythematosus and lupus nephritis, we increasingly understand the underlying drivers of B cell-driven ...

“The team at Kezar has made great progress towards ... the safety events that occurred in the PALIZADE trial in lupus nephritis, including deaths that occurred in both the placebo and drug ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Attendees can also look forward to the unveiling of new lupus nephritis guidelines, reflecting over a year of effort by experts. Additionally, there will be sessions on the potential of cell ...

Kezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as many months. The FDA told the San-Francisco based biotech to halt the PALIZADE study ...